Chan YH, Lee HF, Wang CL, et al. - Given the assessment of rivaroxaban (20/15 mg/d) in comparison to warfarin was done in patients with atrial fibrillation (AF) in the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), and rivaroxaban (15/10 mg/d) was compared with warfarin in Japanese patients with atrial fibrillation in a separate trial, J-ROCKET AF (Japanese ROCKET AF), researchers intended to generate data regarding rivaroxaban following J-ROCKET AF criteria vs warfarin and ROCKET AF dosage, via this retrospective analysis utilizing data from a multicenter healthcare provider in Taiwan. Findings revealed that the observed efficacy of the J-ROCKET AF dosage was equal to that of the ROCKET AF dosage in Asian patients with atrial fibrillation, regardless of renal function. Patients with an estimated glomerular filtration rate < 50 mL/min per 1.73 m² demonstrated lower risk of major bleeding with the J-ROCKET AF dosage. Findings also revealed the efficacy and even greater safety of rivaroxaban following either dosage criteria than warfarin.